Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin
| العنوان: | Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin |
|---|---|
| المؤلفون: | J.W. de Fijter, O. M. H. Tysma, Bart O. Roep, P. Van De Linde, Frans H.J. Claas, D.L. Roelen, P. J. M. vd Boog, J. F. Elliott |
| المصدر: | Clinical and Experimental Immunology. 149:56-62 |
| بيانات النشر: | Oxford University Press (OUP), 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Adult, Graft Rejection, Male, Interleukin 2, Daclizumab, Translational Studies, medicine.medical_treatment, T cell, Immunology, Antibodies, Monoclonal, Humanized, Autoantigens, Immune system, Insulin-Secreting Cells, Immune Tolerance, Humans, Immunology and Allergy, Medicine, IL-2 receptor, Antilymphocyte Serum, Immunosuppression Therapy, business.industry, Antibodies, Monoclonal, Receptors, Interleukin-2, Immunosuppression, Middle Aged, Kidney Transplantation, Recombinant Proteins, eye diseases, CD4 Lymphocyte Count, Anti-thymocyte globulin, Transplantation, Cross-Sectional Studies, Diabetes Mellitus, Type 1, medicine.anatomical_structure, Immunoglobulin G, Interleukin-2, Female, Pancreas Transplantation, business, Immunologic Memory, Immunosuppressive Agents, medicine.drug |
| الوصف: | Summary Pancreas transplantation in type 1 diabetes patients could result in (re)activation of allo- and autoreactive T lymphocytes. Anti-thymocyte globulin (ATG) induction treatment is a successful, but broadly reactive anti-lymphocyte therapy used in pancreas and islet transplantation. A more selective alternative is daclizumab, a monoclonal antibody directed against the interleukin-2 receptor (CD25) on activated lymphocytes. We tested the hypothesis that daclizumab is more selective and has less immunological side effects than ATG. Thirty-nine simultaneous pancreas–kidney transplantation patients with type 1 diabetes were randomized for induction therapy with ATG or daclizumab. Auto- and recall immunity was measured cross-sectionally by lymphocyte stimulation tests with a series of auto- and recall antigens in 35 successfully transplanted patients. T cell autoimmunity to islets was low in both groups, except for a marginal but significantly higher reactivity against glutamic acid decarboxylase (GAD)65 in daclizumab-treated patients. The memory responses to recall antigens were significantly higher in the daclizumab-treated group compared to ATG-treated patients, specifically against purified protein derivative (PPD) (anti-bacterial immunity), Haemophilus influenzae virus matrix protein-1 (anti-viral immunity) and p53 [anti-tumour (auto)immunity]. These data imply that daclizumab is more specifically affecting diabetes-related immune responses than ATG. The autoimmunity is affected effectively after daclizumab induction, while memory responses towards bacterial, viral and tumour antigens are preserved. |
| تدمد: | 1365-2249 0009-9104 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe8a3b711283d56de0839712fad30e8bTest https://doi.org/10.1111/j.1365-2249.2007.03400.xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fe8a3b711283d56de0839712fad30e8b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652249 00099104 |
|---|